Abstract
PURPOSE: To assess minimum 2-year outcomes in patients treated with biocomposite anchors for impingement cysts of the femoral neck during hip arthroscopy for femoroacetabular impingement. METHODS: Patients aged 18 to 65 years who underwent treatment of a femoral neck impingement cyst with placement of a suture anchor by the senior surgeon between January 1, 2007, and December 1, 2019, and were eligible for a minimum 2-year follow-up were identified. Demographic, surgical, and patient-reported outcomes-including Hip Outcome Score-Activities of Daily Living (HOS-ADL), Hip Outcome Score-Sport (HOS-SSS), modified Harris Hip Score (mHHS), patient satisfaction, and Tegner Activity Scale-were retrospectively reviewed from the senior surgeon's prospectively collected database. Complications, including femoral neck fracture, need for revision, or conversion to total hip arthroplasty, were assessed from patient charts and postoperative follow-up surveys. Postoperative magnetic resonance images were assessed for suture anchor integration and presence of a residual cyst. RESULTS: Fifty patients (50 hips) met inclusion criteria, with a median age at surgery of 45 (range, 19-63) years. Minimum 2-year follow-up was obtained for 43 of 50 (86%) patients, with a mean follow-up time of 3.4 ± 1.4 years. One patient reported conversion to total hip arthroplasty, and no additional patients reported revision surgery or postoperative femoral neck fractures. HOS-ADL, HOS-SSS, mHHS, Western Ontario and McMaster Universities Osteoarthritis Index, and Short Form 12 Physical Component Summary scores significantly improved after hip arthroscopy (P < .001), with most patients attaining minimum clinically significant difference and patient acceptable symptom state for HOS-ADL, HOS-SSS, and mHHS. Notably, the median postoperative patient satisfaction score was 9.0 of 10 (range, 1-10). CONCLUSIONS: Hips with femoral neck impingement cysts treated with biocomposite suture anchors showed excellent patient-reported outcomes and high survivorship at a minimum 2-year follow-up, with most patients achieving mHHS minimum clinically significant difference and patient acceptable symptom state. LEVEL OF EVIDENCE: Level IV, retrospective therapeutic case series.